Biomarkers /
ERBB2
Back to Biomarkers List
Overview
ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, also known as HER2 and neu) is a gene that encodes for the receptor tyrosine-protein kinase erbB-2. ERBB2 has been found to be amplified with an increased copy number in several cancers (PMID: 20185938). Amplification of ERBB2 promotes tumorigenesis and pathogenesis of several human cancers (PMID: 17471238). Recently, in breast cancer patients without ERBB2 gene amplification, activating ERBB2 mutations have also been identified (PMID: 23220880).
ERBB2 is altered in 5.46% of all cancers with breast carcinoma, non-small cell lung carcinoma, colorectal adenocarcinoma, bladder carcinoma, and uterine corpus neoplasm having the greatest prevalence of alterations [3].
The most common alterations in ERBB2 are ERBB2 Amplification (3.82%), ERBB2 Mutation (3.69%), ERBB2 S310F (0.32%), ERBB2 Y772_A775dup (0.28%), and ERBB2 L755S (0.23%) [3].
Biomarker-Directed Therapies
ERBB2 is a predictive biomarker for use of trastuzumab, aromatase inhibitor, docetaxel, paclitaxel, pertuzumab, ribociclib, abemaciclib, carboplatin, everolimus, exemestane, fulvestrant, lapatinib, trastuzumab emtansine, capecitabine, cisplatin, letrozole, palbociclib, alpelisib, anastrozole, atezolizumab, endocrine therapy, fluorouracil, nab-paclitaxel, neratinib, olaparib, talazoparib, taxane compound, and trastuzumab/hyaluronidase-oysk in patients.
Breast carcinoma, adenocarcinoma of the gastroesophageal junction, gastric carcinoma, malignant esophageal neoplasm, and non-small cell lung carcinoma have the most therapies with ERBB2 as a predictive biomarker.
Of the therapies with ERBB2 as a predictive biomarker, 23 are FDA-approved in at least one clinical setting and 20 have NCCN guidelines in at least one clinical setting.
ERBB2 Amplification, ERBB2 Loss, ERBB2 D769Y, ERBB2 Exon 20 Insertion, and ERBB2 I767M are the top alterations on ERBB2 targeted by therapies [4].
Abemaciclib +
Everolimus +
Lapatinib +
Breast Carcinoma -
Letrozole +
Neratinib +
Olaparib +
Breast Carcinoma -
Pertuzumab +
Talazoparib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. |
Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, MCG), Metastatic (FDA, MCG) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (BNF, SMC), Metastatic (NICE, BNF, SMC), Neoadjuvant (BNF, SMC) |
Gastric Carcinoma -
Malignant Esophageal Neoplasm -
Trastuzumab Emtansine +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN, MCG, ASCO), Recurrent (NCCN, MCG) | |
| Note: Indicated (as a single agent) for the treatment of patients with HER2-positive breast cancer in either the adjuvant or metastatic setting who previously received trastuzumab and a taxane, separately or in combination. |
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN. |
Trastuzumab/hyaluronidase-Oysk +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA), Metastatic (FDA) | |
| Note: A ready-to-use combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase-oysk, an endoglycosidase, are indicated in adults for the treatment of HER2-overexpressing breast cancer. |
Abemaciclib + Aromatase Inhibitor +
Abemaciclib + Fulvestrant +
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
Anastrozole + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Aromatase Inhibitor + Ribociclib +
Aromatase Inhibitor + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (MCG, SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Atezolizumab + Nab-Paclitaxel +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Atezolizumab (TECENTRIQ®, Genentech Inc.) is approved in combination with paclitaxel protein-bound for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test. |
Capecitabine + Cisplatin + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Capecitabine + Lapatinib +
Breast Carcinoma -
Carboplatin + Docetaxel + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (SMC) |
Carboplatin + Paclitaxel + Trastuzumab +
Cisplatin + Fluorouracil + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Docetaxel + Pertuzumab + Trastuzumab +
Breast Carcinoma -
Docetaxel + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (MCG), Metastatic (MCG) |
Endocrine Therapy + Lapatinib +
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) |
Exemestane + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. |
Fulvestrant + Palbociclib +
Letrozole + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. |
Paclitaxel + Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN, MCG), Metastatic (NCCN, MCG), Neoadjuvant (NCCN, MCG), Recurrent (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Neoadjuvant (NICE) |
Paclitaxel + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN, MCG), Metastatic (NCCN, MCG), Neoadjuvant (NCCN, MCG), Recurrent (NCCN, MCG) |
Clinical Trials
ERBB2 status serves as an inclusion eligibility criteria in 992 clinical trials, of which 825 are open and 167 are closed. Of the trials that contain ERBB2 status as an inclusion criterion, 16 are early phase 1 (13 open), 258 are phase 1 (198 open), 143 are phase 1/phase 2 (120 open), 413 are phase 2 (352 open), 13 are phase 2/phase 3 (9 open), 114 are phase 3 (103 open), 2 are phase 4 (1 open), and 33 are no phase specified (29 open).
Trials with ERBB2 status in the inclusion eligibility criteria most commonly target breast carcinoma, malignant solid tumor, non-small cell lung carcinoma, gastric carcinoma, and ovarian carcinoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are ERBB2 Loss, ERBB2 Amplification, and ERBB2 Mutation [4].
Trastuzumab, paclitaxel, pembrolizumab, carboplatin, and fulvestrant are the most frequent therapies in trials with ERBB2 as an inclusion criteria [4].
Significance of ERBB2 in Diseases
Breast Carcinoma +
ERBB2 is mutated in 14.05% of breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 862 clinical trials for breast carcinoma, of which 713 are open and 149 are closed. Of the trials that contain ERBB2 status and breast carcinoma as inclusion criteria, 14 are early phase 1 (12 open), 229 are phase 1 (175 open), 128 are phase 1/phase 2 (108 open), 355 are phase 2 (297 open), 11 are phase 2/phase 3 (8 open), 97 are phase 3 (89 open), 2 are phase 4 (1 open), and 26 are no phase specified (23 open) [4].
Trastuzumab, everolimus, exemestane, aromatase inhibitor, docetaxel, carboplatin, paclitaxel, pertuzumab, trastuzumab emtansine, fulvestrant, palbociclib, taxane compound, talazoparib, olaparib, neratinib, letrozole, ribociclib, lapatinib, abemaciclib, endocrine therapy, capecitabine, atezolizumab, nab-paclitaxel, anastrozole, alpelisib, and trastuzumab/hyaluronidase-oysk are currently approved for use in patients with ERBB2 mutation in breast carcinoma [4].
Trastuzumab, paclitaxel, and carboplatin are the most frequent therapies in breast carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Non-Small Cell Lung Carcinoma +
ERBB2 is mutated in 4.12% of non-small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 86 clinical trials for non-small cell lung carcinoma, of which 68 are open and 18 are closed. Of the trials that contain ERBB2 status and non-small cell lung carcinoma as inclusion criteria, 41 are phase 1 (28 open), 22 are phase 1/phase 2 (17 open), and 23 are phase 2 (23 open) [4].
Trastuzumab emtansine is currently approved for use in patients with ERBB2 mutation in non-small cell lung carcinoma [4].
Pembrolizumab, atezolizumab, and carboplatin are the most frequent therapies in non-small cell lung carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Gastric Carcinoma +
ERBB2 is mutated in 10.05% of gastric carcinoma patients [3].
ERBB2 is an inclusion criterion in 58 clinical trials for gastric carcinoma, of which 47 are open and 11 are closed. Of the trials that contain ERBB2 status and gastric carcinoma as inclusion criteria, 26 are phase 1 (19 open), 16 are phase 1/phase 2 (14 open), 12 are phase 2 (11 open), 1 is phase 2/phase 3 (0 open), and 3 are phase 3 (3 open) [4].
Capecitabine, cisplatin, trastuzumab, and fluorouracil are currently approved for use in patients with ERBB2 mutation in gastric carcinoma [4].
Pembrolizumab, atezolizumab, and trastuzumab are the most frequent therapies in gastric carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Adenocarcinoma Of The Gastroesophageal Junction +
ERBB2 is mutated in 20.96% of adenocarcinoma of the gastroesophageal junction patients [3].
ERBB2 is an inclusion criterion in 53 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 42 are open and 11 are closed. Of the trials that contain ERBB2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 16 are phase 1 (14 open), 8 are phase 1/phase 2 (5 open), 17 are phase 2 (15 open), 2 are phase 2/phase 3 (1 open), 9 are phase 3 (7 open), and 1 is no phase specified (0 open) [4].
Capecitabine, cisplatin, trastuzumab, and fluorouracil are currently approved for use in patients with ERBB2 mutation in adenocarcinoma of the gastroesophageal junction [4].
Pembrolizumab, trastuzumab, and placebo are the most frequent therapies in adenocarcinoma of the gastroesophageal junction trials with ERBB2 alterations as inclusion criteria [4].
Malignant Esophageal Neoplasm +
Trastuzumab is currently approved for use in patients with ERBB2 mutation in malignant esophageal neoplasm [4].
Malignant Solid Tumor +
ERBB2 is mutated in 2.2% of malignant solid tumor patients [3].
ERBB2 is an inclusion criterion in 131 clinical trials for malignant solid tumor, of which 105 are open and 26 are closed. Of the trials that contain ERBB2 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 88 are phase 1 (69 open), 29 are phase 1/phase 2 (22 open), and 13 are phase 2 (13 open) [4].
Paclitaxel, palbociclib, and trastuzumab are the most frequent therapies in malignant solid tumor trials with ERBB2 alterations as inclusion criteria [4].
Ovarian Carcinoma +
ERBB2 is an inclusion criterion in 55 clinical trials for ovarian carcinoma, of which 42 are open and 13 are closed. Of the trials that contain ERBB2 status and ovarian carcinoma as inclusion criteria, 32 are phase 1 (21 open), 17 are phase 1/phase 2 (15 open), and 6 are phase 2 (6 open) [4].
Pembrolizumab, durvalumab, and olaparib are the most frequent therapies in ovarian carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Colorectal Carcinoma +
ERBB2 is mutated in 2.33% of colorectal carcinoma patients [3].
ERBB2 is an inclusion criterion in 51 clinical trials for colorectal carcinoma, of which 42 are open and 9 are closed. Of the trials that contain ERBB2 status and colorectal carcinoma as inclusion criteria, 29 are phase 1 (23 open), 14 are phase 1/phase 2 (11 open), and 8 are phase 2 (8 open) [4].
Pembrolizumab, trastuzumab, and atezolizumab are the most frequent therapies in colorectal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Gastric Adenocarcinoma +
ERBB2 is mutated in 9.57% of gastric adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 35 clinical trials for gastric adenocarcinoma, of which 27 are open and 8 are closed. Of the trials that contain ERBB2 status and gastric adenocarcinoma as inclusion criteria, 9 are phase 1 (7 open), 5 are phase 1/phase 2 (4 open), 12 are phase 2 (10 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (5 open), and 1 is no phase specified (0 open) [4].
Pembrolizumab, placebo, and trastuzumab are the most frequent therapies in gastric adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Melanoma +
ERBB2 is mutated in 3.03% of melanoma patients [3].
ERBB2 is an inclusion criterion in 33 clinical trials for melanoma, of which 27 are open and 6 are closed. Of the trials that contain ERBB2 status and melanoma as inclusion criteria, 1 is early phase 1 (1 open), 20 are phase 1 (15 open), 6 are phase 1/phase 2 (6 open), and 6 are phase 2 (5 open) [4].
Pembrolizumab, atezolizumab, and spartalizumab are the most frequent therapies in melanoma trials with ERBB2 alterations as inclusion criteria [4].
Head And Neck Squamous Cell Carcinoma +
ERBB2 is mutated in 2.59% of head and neck squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 33 clinical trials for head and neck squamous cell carcinoma, of which 26 are open and 7 are closed. Of the trials that contain ERBB2 status and head and neck squamous cell carcinoma as inclusion criteria, 22 are phase 1 (17 open), 7 are phase 1/phase 2 (6 open), and 4 are phase 2 (3 open) [4].
Pembrolizumab, atezolizumab, and durvalumab are the most frequent therapies in head and neck squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Pancreatic Carcinoma +
ERBB2 is mutated in 2.2% of pancreatic carcinoma patients [3].
ERBB2 is an inclusion criterion in 29 clinical trials for pancreatic carcinoma, of which 22 are open and 7 are closed. Of the trials that contain ERBB2 status and pancreatic carcinoma as inclusion criteria, 16 are phase 1 (11 open), 10 are phase 1/phase 2 (8 open), and 3 are phase 2 (3 open) [4].
Spartalizumab, nivolumab, and ipilimumab are the most frequent therapies in pancreatic carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Renal Cell Carcinoma +
ERBB2 is mutated in 0.91% of renal cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 27 clinical trials for renal cell carcinoma, of which 23 are open and 4 are closed. Of the trials that contain ERBB2 status and renal cell carcinoma as inclusion criteria, 19 are phase 1 (16 open), 6 are phase 1/phase 2 (6 open), and 2 are phase 2 (1 open) [4].
Pembrolizumab, atezolizumab, and pi3k-delta inhibitor incb050465 are the most frequent therapies in renal cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Urothelial Carcinoma +
ERBB2 is mutated in 15.52% of urothelial carcinoma patients [3].
ERBB2 is an inclusion criterion in 25 clinical trials for urothelial carcinoma, of which 22 are open and 3 are closed. Of the trials that contain ERBB2 status and urothelial carcinoma as inclusion criteria, 13 are phase 1 (10 open), 8 are phase 1/phase 2 (8 open), and 4 are phase 2 (4 open) [4].
Pembrolizumab, epacadostat, and nivolumab are the most frequent therapies in urothelial carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Small Cell Lung Carcinoma +
ERBB2 is mutated in 3.16% of small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 22 clinical trials for small cell lung carcinoma, of which 20 are open and 2 are closed. Of the trials that contain ERBB2 status and small cell lung carcinoma as inclusion criteria, 9 are phase 1 (8 open), 10 are phase 1/phase 2 (9 open), and 3 are phase 2 (3 open) [4].
Pembrolizumab, olaparib, and gemcitabine are the most frequent therapies in small cell lung carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Fallopian Tube Carcinoma +
ERBB2 is an inclusion criterion in 22 clinical trials for fallopian tube carcinoma, of which 17 are open and 5 are closed. Of the trials that contain ERBB2 status and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 14 are phase 1 (9 open), 5 are phase 1/phase 2 (5 open), and 2 are phase 2 (2 open) [4].
Olaparib, carboplatin, and gemcitabine are the most frequent therapies in fallopian tube carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Esophageal Carcinoma +
ERBB2 is mutated in 17.78% of esophageal carcinoma patients [3].
ERBB2 is an inclusion criterion in 21 clinical trials for esophageal carcinoma, of which 16 are open and 5 are closed. Of the trials that contain ERBB2 status and esophageal carcinoma as inclusion criteria, 6 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), 8 are phase 2 (8 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Pembrolizumab, adct-601, and azd4547 are the most frequent therapies in esophageal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Endometrial Carcinoma +
ERBB2 is mutated in 8.48% of endometrial carcinoma patients [3].
ERBB2 is an inclusion criterion in 21 clinical trials for endometrial carcinoma, of which 19 are open and 2 are closed. Of the trials that contain ERBB2 status and endometrial carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (7 open), 8 are phase 1/phase 2 (7 open), and 4 are phase 2 (4 open) [4].
Pembrolizumab, vistusertib, and adenosine-a2a receptor antagonist cpi-444 are the most frequent therapies in endometrial carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Prostate Carcinoma +
ERBB2 is mutated in 0.96% of prostate carcinoma patients [3].
ERBB2 is an inclusion criterion in 19 clinical trials for prostate carcinoma, of which 15 are open and 4 are closed. Of the trials that contain ERBB2 status and prostate carcinoma as inclusion criteria, 12 are phase 1 (8 open), 4 are phase 1/phase 2 (4 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].
Enzalutamide, docetaxel, and adenosine-a2a receptor antagonist cpi-444 are the most frequent therapies in prostate carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Primary Peritoneal Carcinoma +
ERBB2 is an inclusion criterion in 18 clinical trials for primary peritoneal carcinoma, of which 13 are open and 5 are closed. Of the trials that contain ERBB2 status and primary peritoneal carcinoma as inclusion criteria, 12 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (2 open) [4].
Olaparib, gemcitabine, and carboplatin are the most frequent therapies in primary peritoneal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Breast Adenocarcinoma +
ERBB2 is mutated in 9.74% of breast adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 17 clinical trials for breast adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain ERBB2 status and breast adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), 5 are phase 3 (4 open), and 2 are no phase specified (2 open) [4].
Palbociclib, surgery, and sar439859 are the most frequent therapies in breast adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Bladder Carcinoma +
ERBB2 is mutated in 15.42% of bladder carcinoma patients [3].
ERBB2 is an inclusion criterion in 15 clinical trials for bladder carcinoma, of which 12 are open and 3 are closed. Of the trials that contain ERBB2 status and bladder carcinoma as inclusion criteria, 11 are phase 1 (8 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].
Pembrolizumab, atezolizumab, and adenosine-a2a receptor antagonist cpi-444 are the most frequent therapies in bladder carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Lymphoma +
ERBB2 is mutated in 1.34% of lymphoma patients [3].
ERBB2 is an inclusion criterion in 12 clinical trials for lymphoma, of which 9 are open and 3 are closed. Of the trials that contain ERBB2 status and lymphoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].
Dasatinib, gamma-secretase inhibitor ly3039478, and nivolumab are the most frequent therapies in lymphoma trials with ERBB2 alterations as inclusion criteria [4].
Hepatocellular Carcinoma +
ERBB2 is an inclusion criterion in 12 clinical trials for hepatocellular carcinoma, of which 10 are open and 2 are closed. Of the trials that contain ERBB2 status and hepatocellular carcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [4].
Anti-muc1 car-transduced autologous t-lymphocytes, anti-pd1/ctla4 bispecific antibody xmab20717, and gamma-secretase inhibitor ly3039478 are the most frequent therapies in hepatocellular carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Cervical Carcinoma +
ERBB2 is mutated in 9.06% of cervical carcinoma patients [3].
ERBB2 is an inclusion criterion in 10 clinical trials for cervical carcinoma, of which 8 are open and 2 are closed. Of the trials that contain ERBB2 status and cervical carcinoma as inclusion criteria, 7 are phase 1 (5 open) and 3 are phase 1/phase 2 (3 open) [4].
Pembrolizumab, adenosine-a2a receptor antagonist cpi-444, and cpi-006 are the most frequent therapies in cervical carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Head And Neck Carcinoma +
ERBB2 is mutated in 2.52% of head and neck carcinoma patients [3].
ERBB2 is an inclusion criterion in 9 clinical trials for head and neck carcinoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 status and head and neck carcinoma as inclusion criteria, 8 are phase 1 (6 open) and 1 is phase 2 (1 open) [4].
Spartalizumab, adenosine a2a receptor antagonist nir178, and adenosine-a2a receptor antagonist cpi-444 are the most frequent therapies in head and neck carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Glioblastoma +
ERBB2 is mutated in 1.84% of glioblastoma patients [3].
ERBB2 is an inclusion criterion in 9 clinical trials for glioblastoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 status and glioblastoma as inclusion criteria, 4 are phase 1 (3 open), 4 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].
Akt/erk inhibitor onc201, csf-1r inhibitor blz945, and extended release flucytosine are the most frequent therapies in glioblastoma trials with ERBB2 alterations as inclusion criteria [4].
Pancreatic Adenocarcinoma +
ERBB2 is mutated in 2.14% of pancreatic adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 9 clinical trials for pancreatic adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERBB2 status and pancreatic adenocarcinoma as inclusion criteria, 4 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].
Anetumab ravtansine, anti-pd-l1 monoclonal antibody ly3300054, and tislelizumab are the most frequent therapies in pancreatic adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Ductal Carcinoma In Situ +
ERBB2 is mutated in 2.86% of ductal carcinoma in situ patients [3].
ERBB2 is an inclusion criterion in 8 clinical trials for ductal carcinoma in situ, of which 7 are open and 1 is closed. Of the trials that contain ERBB2 status and ductal carcinoma in situ as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 2 are phase 2 (1 open), and 2 are no phase specified (2 open) [4].
Radiation therapy, her2-pulsed autologous type-1 polarized dendritic cell vaccine, and observation are the most frequent therapies in ductal carcinoma in situ trials with ERBB2 alterations as inclusion criteria [4].
Soft Tissue Sarcoma +
ERBB2 is mutated in 0.93% of soft tissue sarcoma patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for soft tissue sarcoma, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 status and soft tissue sarcoma as inclusion criteria, 5 are phase 1 (4 open) and 2 are phase 1/phase 2 (2 open) [4].
Adct-601, cisplatin, and taladegib are the most frequent therapies in soft tissue sarcoma trials with ERBB2 alterations as inclusion criteria [4].
Breast Invasive Ductal Carcinoma +
ERBB2 is mutated in 14.7% of breast invasive ductal carcinoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for breast invasive ductal carcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and breast invasive ductal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), 1 is phase 3 (1 open), and 3 are no phase specified (3 open) [4].
Radiation therapy, surgery, and cryoablation are the most frequent therapies in breast invasive ductal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Colorectal Adenocarcinoma +
ERBB2 is mutated in 4.73% of colorectal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for colorectal adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERBB2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].
Pembrolizumab, e7130, and flx475 are the most frequent therapies in colorectal adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Cancer +
ERBB2 is mutated in 1.46% of cancer patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for cancer, of which 4 are open and 2 are closed. Of the trials that contain ERBB2 status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].
Pi3k/mtor inhibitor ly3023414, cisplatin, and pemetrexed are the most frequent therapies in cancer trials with ERBB2 alterations as inclusion criteria [4].
Sarcoma +
ERBB2 is mutated in 1.14% of sarcoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for sarcoma, of which 4 are open and 2 are closed. Of the trials that contain ERBB2 status and sarcoma as inclusion criteria, 4 are phase 1 (3 open) and 2 are phase 1/phase 2 (1 open) [4].
Pembrolizumab, adenosine-a2a receptor antagonist cpi-444, and gemcitabine are the most frequent therapies in sarcoma trials with ERBB2 alterations as inclusion criteria [4].
Non-Hodgkin Lymphoma +
ERBB2 is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) and 3 are phase 2 (3 open) [4].
Pi3k/mtor inhibitor ly3023414, midazolam, and fulvestrant are the most frequent therapies in non-hodgkin lymphoma trials with ERBB2 alterations as inclusion criteria [4].
Pancreatic Ductal Adenocarcinoma +
ERBB2 is an inclusion criterion in 6 clinical trials for pancreatic ductal adenocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Pembrolizumab, pi3k-delta inhibitor incb050465, and itacitinib are the most frequent therapies in pancreatic ductal adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Esophageal Adenocarcinoma +
ERBB2 is mutated in 19.46% of esophageal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for esophageal adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [4].
Trastuzumab, zw49, and avelumab are the most frequent therapies in esophageal adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Squamous Cell Lung Carcinoma +
ERBB2 is mutated in 2.31% of squamous cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and squamous cell lung carcinoma as inclusion criteria, 4 are phase 1 (4 open) and 1 is phase 1/phase 2 (1 open) [4].
Vistusertib, azd8186, and pi3k/mtor inhibitor ly3023414 are the most frequent therapies in squamous cell lung carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Multiple Myeloma +
ERBB2 is an inclusion criterion in 5 clinical trials for multiple myeloma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [4].
Pertuzumab, nivolumab, and dasatinib are the most frequent therapies in multiple myeloma trials with ERBB2 alterations as inclusion criteria [4].
Nasopharyngeal Carcinoma +
ERBB2 is an inclusion criterion in 5 clinical trials for nasopharyngeal carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and nasopharyngeal carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Pembrolizumab, adct-601, and flx475 are the most frequent therapies in nasopharyngeal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Peritoneal Mesothelioma +
ERBB2 is an inclusion criterion in 5 clinical trials for peritoneal mesothelioma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and peritoneal mesothelioma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [4].
Anetumab ravtansine, everolimus, and pemetrexed are the most frequent therapies in peritoneal mesothelioma trials with ERBB2 alterations as inclusion criteria [4].
Inflammatory Breast Carcinoma +
ERBB2 is mutated in 8.33% of inflammatory breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for inflammatory breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and inflammatory breast carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [4].
Cyclophosphamide, pertuzumab, and trastuzumab are the most frequent therapies in inflammatory breast carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Cholangiocarcinoma +
ERBB2 is mutated in 3.9% of cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for cholangiocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and cholangiocarcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Gamma-secretase inhibitor ly3039478, pi3k/mtor inhibitor ly3023414, and vistusertib are the most frequent therapies in cholangiocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Mesothelioma +
ERBB2 is an inclusion criterion in 4 clinical trials for mesothelioma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and mesothelioma as inclusion criteria, 4 are phase 1 (3 open) [4].
Adct-601, cd40 agonist monoclonal antibody ro7009789, and incagn02385 are the most frequent therapies in mesothelioma trials with ERBB2 alterations as inclusion criteria [4].
Peritoneal Carcinoma +
ERBB2 is an inclusion criterion in 4 clinical trials for peritoneal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (3 open) [4].
Anti-b7-h4 monoclonal antibody fpa150, parp inhibitor bgb-290, and yttrium y 90 anti-cdh3 monoclonal antibody ff-21101 are the most frequent therapies in peritoneal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Esophagogastric Carcinoma +
ERBB2 is mutated in 20.53% of esophagogastric carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for esophagogastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and esophagogastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Anti-cd25-pbd antibody-drug conjugate adct-301, monoclonal microbial edp1503, and fluorouracil are the most frequent therapies in esophagogastric carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Esophageal Squamous Cell Carcinoma +
ERBB2 is mutated in 7.45% of esophageal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for esophageal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Ly3143921 hydrate, porcupine inhibitor wnt974, and irinotecan are the most frequent therapies in esophageal squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Diffuse Large B-Cell Lymphoma +
ERBB2 is mutated in 2.49% of diffuse large B-cell lymphoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Adenosine a2a receptor antagonist nir178, bay1143572, and incagn02385 are the most frequent therapies in diffuse large B-cell lymphoma trials with ERBB2 alterations as inclusion criteria [4].
Malignant Ovarian Epithelial Tumor +
ERBB2 is mutated in 4.4% of malignant ovarian epithelial tumor patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for malignant ovarian epithelial tumor, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 1 (2 open) [4].
Anti-b7-h4 monoclonal antibody fpa150, yttrium y 90 anti-cdh3 monoclonal antibody ff-21101, and olaparib are the most frequent therapies in malignant ovarian epithelial tumor trials with ERBB2 alterations as inclusion criteria [4].
Acute Myeloid Leukemia +
ERBB2 is mutated in 1.09% of acute myeloid leukemia patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1/phase 2 (3 open) [4].
Autologous nkg2d car-expressing t-lymphocytes cm-cs1, gm-csf, and galinpepimut-s are the most frequent therapies in acute myeloid leukemia trials with ERBB2 alterations as inclusion criteria [4].
Gastrointestinal Stromal Tumor +
ERBB2 is mutated in 0.85% of gastrointestinal stromal tumor patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in gastrointestinal stromal tumor trials with ERBB2 alterations as inclusion criteria [4].
Merkel Cell Carcinoma +
ERBB2 is mutated in 0.54% of Merkel cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for Merkel cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Aldesleukin prodrug nktr-214, incagn02385, and peg-conjugated tlr7/8 agonist nktr-262 are the most frequent therapies in Merkel cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Pleural Mesothelioma +
ERBB2 is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and pleural mesothelioma as inclusion criteria, 3 are phase 1 (2 open) [4].
Anetumab ravtansine, itraconazole, and mga271 are the most frequent therapies in pleural mesothelioma trials with ERBB2 alterations as inclusion criteria [4].
Lobular Breast Carcinoma +
ERBB2 is mutated in 12.13% of lobular breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for lobular breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and lobular breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Partial breast irradiation, crizotinib, and fulvestrant are the most frequent therapies in lobular breast carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Gallbladder Carcinoma +
ERBB2 is mutated in 11.11% of gallbladder carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for gallbladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and gallbladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Irinotecan, lenvatinib, and pembrolizumab are the most frequent therapies in gallbladder carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Endometrial Adenocarcinoma +
ERBB2 is mutated in 9.25% of endometrial adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for endometrial adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and endometrial adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Morab-202, pi3k-delta inhibitor incb050465, and epacadostat are the most frequent therapies in endometrial adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Colon Carcinoma +
ERBB2 is mutated in 5.67% of colon carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for colon carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and colon carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Adenosine a2a receptor antagonist nir178, gamma-secretase inhibitor ly3039478, and pi3k/mtor inhibitor ly3023414 are the most frequent therapies in colon carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Malignant Salivary Gland Neoplasm +
ERBB2 is mutated in 3.33% of malignant salivary gland neoplasm patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in malignant salivary gland neoplasm trials with ERBB2 alterations as inclusion criteria [4].
Chronic Lymphocytic Leukemia +
ERBB2 is mutated in 2.45% of chronic lymphocytic leukemia patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 0 are open and 2 are closed. Of the trials that contain ERBB2 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [4].
Gamma-secretase inhibitor ly3039478, ror1 car-specific autologous t-lymphocytes, and prednisone are the most frequent therapies in chronic lymphocytic leukemia trials with ERBB2 alterations as inclusion criteria [4].
Bile Duct Carcinoma +
ERBB2 is mutated in 3.85% of bile duct carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for bile duct carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and bile duct carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Trastuzumab, cisplatin, and gemcitabine are the most frequent therapies in bile duct carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Lung Carcinoma +
ERBB2 is mutated in 2.72% of lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and lung carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Ifetroban sodium, dacomitinib, and placebo are the most frequent therapies in lung carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Thymic Carcinoma +
ERBB2 is mutated in 1.37% of thymic carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for thymic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and thymic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in thymic carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Leukemia +
ERBB2 is mutated in 1.25% of leukemia patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for leukemia, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and leukemia as inclusion criteria, 2 are phase 1 (1 open) [4].
Her2 ecd+tm virus-like replicon particles vaccine avx901, anti-pd-1/anti-lag-3 dart protein mgd013, and margetuximab are the most frequent therapies in leukemia trials with ERBB2 alterations as inclusion criteria [4].
Myelodysplastic Syndromes +
ERBB2 is mutated in 0.76% of myelodysplastic syndromes patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].
Autologous nkg2d car-expressing t-lymphocytes cm-cs1 and jak1 inhibitor incb052793 are the most frequent therapies in myelodysplastic syndromes trials with ERBB2 alterations as inclusion criteria [4].
Prostate Adenocarcinoma +
ERBB2 is mutated in 0.87% of prostate adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Odm-209, ipatasertib, and rucaparib are the most frequent therapies in prostate adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Ureter Urothelial Carcinoma +
ERBB2 is an inclusion criterion in 2 clinical trials for ureter urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and ureter urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Gsk3326595, pi3k-delta inhibitor incb050465, and itacitinib are the most frequent therapies in ureter urothelial carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Duct Carcinoma +
ERBB2 is mutated in 27.16% of salivary duct carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary duct carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Carcinoma, NOS +
ERBB2 is mutated in 16.67% of salivary carcinoma, NOS patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary carcinoma, NOS as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary carcinoma, NOS trials with ERBB2 alterations as inclusion criteria [4].
Small Intestinal Adenocarcinoma +
ERBB2 is mutated in 14.75% of small intestinal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Bladder Urothelial Carcinoma +
ERBB2 is mutated in 16.45% of bladder urothelial carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Gsk3326595 is the most frequent therapy in bladder urothelial carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Gland Adenocarcinoma +
ERBB2 is mutated in 17.01% of salivary gland adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary gland adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Small Intestinal Carcinoma +
ERBB2 is mutated in 10.81% of small intestinal carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Irinotecan and trastuzumab are the most frequent therapies in small intestinal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +
ERBB2 is mutated in 11.27% of infiltrating renal pelvis and ureter urothelial carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Gsk3326595 is the most frequent therapy in infiltrating renal pelvis and ureter urothelial carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Ampulla Of Vater Carcinoma +
ERBB2 is mutated in 8.82% of ampulla of vater carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Irinotecan and trastuzumab are the most frequent therapies in ampulla of vater carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Digestive System Carcinoma +
ERBB2 is mutated in 13.18% of digestive system carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for digestive system carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and digestive system carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Irinotecan and trastuzumab are the most frequent therapies in digestive system carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Urethral Carcinoma +
ERBB2 is mutated in 8.0% of urethral carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for urethral carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and urethral carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Atezolizumab is the most frequent therapy in urethral carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Extrahepatic Cholangiocarcinoma +
ERBB2 is mutated in 5.8% of extrahepatic cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lenvatinib and pembrolizumab are the most frequent therapies in extrahepatic cholangiocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Ovarian Endometrioid Tumor +
ERBB2 is mutated in 5.42% of ovarian endometrioid tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].
Ipatasertib and rucaparib are the most frequent therapies in ovarian endometrioid tumor trials with ERBB2 alterations as inclusion criteria [4].
Uterine Corpus Carcinosarcoma +
ERBB2 is mutated in 6.77% of uterine corpus carcinosarcoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Adenosine-a2a receptor antagonist cpi-444, cpi-006, and pembrolizumab are the most frequent therapies in uterine corpus carcinosarcoma trials with ERBB2 alterations as inclusion criteria [4].
Cervical Squamous Cell Carcinoma +
ERBB2 is mutated in 6.5% of cervical squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Porcupine inhibitor wnt974 and spartalizumab are the most frequent therapies in cervical squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Gland Acinic Cell Carcinoma +
ERBB2 is mutated in 4.0% of salivary gland acinic cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland acinic cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland acinic cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary gland acinic cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Lung Adenocarcinoma +
ERBB2 is mutated in 4.38% of lung adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Anetumab ravtansine and itraconazole are the most frequent therapies in lung adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Malignant Ovarian Clear Cell Tumor +
ERBB2 is mutated in 5.88% of malignant ovarian clear cell tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (1 open) [4].
Ipatasertib and rucaparib are the most frequent therapies in malignant ovarian clear cell tumor trials with ERBB2 alterations as inclusion criteria [4].
Hematopoietic And Lymphoid Malignancy +
ERBB2 is mutated in 2.7% of hematopoietic and lymphoid malignancy patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Ky1044 and atezolizumab are the most frequent therapies in hematopoietic and lymphoid malignancy trials with ERBB2 alterations as inclusion criteria [4].
Oropharyngeal Squamous Cell Carcinoma +
ERBB2 is mutated in 3.18% of oropharyngeal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cxc chemokine receptor 2 antagonist azd5069, medi-4736, and stat3 antisense oligonucleotide isis 481464 are the most frequent therapies in oropharyngeal squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
ERBB2 is mutated in 2.22% of nasal cavity and paranasal sinus carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
ERBB2 is mutated in 3.48% of high grade ovarian serous adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ipatasertib and rucaparib are the most frequent therapies in high grade ovarian serous adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Neuroendocrine Carcinoma +
ERBB2 is mutated in 2.27% of neuroendocrine carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for neuroendocrine carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and neuroendocrine carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Ferumoxytol, liposomal irinotecan, and veliparib are the most frequent therapies in neuroendocrine carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Oral Cavity Squamous Cell Carcinoma +
ERBB2 is mutated in 2.5% of oral cavity squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cxc chemokine receptor 2 antagonist azd5069, medi-4736, and stat3 antisense oligonucleotide isis 481464 are the most frequent therapies in oral cavity squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Laryngeal Squamous Cell Carcinoma +
ERBB2 is mutated in 1.79% of laryngeal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cxc chemokine receptor 2 antagonist azd5069, medi-4736, and stat3 antisense oligonucleotide isis 481464 are the most frequent therapies in laryngeal squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Thyroid Gland Carcinoma +
ERBB2 is mutated in 1.51% of thyroid gland carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in thyroid gland carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Pancreatic Neuroendocrine Neoplasm +
ERBB2 is mutated in 1.44% of pancreatic neuroendocrine neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Everolimus is the most frequent therapy in pancreatic neuroendocrine neoplasm trials with ERBB2 alterations as inclusion criteria [4].
Anaplastic Astrocytoma +
ERBB2 is mutated in 1.33% of anaplastic astrocytoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in anaplastic astrocytoma trials with ERBB2 alterations as inclusion criteria [4].
Intrahepatic Cholangiocarcinoma +
ERBB2 is mutated in 2.64% of intrahepatic cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lenvatinib and pembrolizumab are the most frequent therapies in intrahepatic cholangiocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Leiomyosarcoma +
ERBB2 is mutated in 1.31% of leiomyosarcoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and leiomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in leiomyosarcoma trials with ERBB2 alterations as inclusion criteria [4].
Ovarian Epithelial Tumor +
ERBB2 is mutated in 2.35% of ovarian epithelial tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Sacituzumab govitecan is the most frequent therapy in ovarian epithelial tumor trials with ERBB2 alterations as inclusion criteria [4].
Clear Cell Renal Cell Carcinoma +
ERBB2 is mutated in 1.31% of clear cell renal cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in clear cell renal cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Medulloblastoma +
ERBB2 is mutated in 1.08% of medulloblastoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and medulloblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Trastuzumab is the most frequent therapy in medulloblastoma trials with ERBB2 alterations as inclusion criteria [4].
Papillary Renal Cell Carcinoma +
ERBB2 is mutated in 0.86% of papillary renal cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in papillary renal cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Rhabdomyosarcoma +
ERBB2 is mutated in 0.86% of rhabdomyosarcoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Pen-866 is the most frequent therapy in rhabdomyosarcoma trials with ERBB2 alterations as inclusion criteria [4].
Glioma +
ERBB2 is mutated in 1.63% of glioma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Trastuzumab is the most frequent therapy in glioma trials with ERBB2 alterations as inclusion criteria [4].
Acute Lymphoblastic Leukemia +
ERBB2 is mutated in 0.68% of acute lymphoblastic leukemia patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Ror1 car-specific autologous t-lymphocytes is the most frequent therapy in acute lymphoblastic leukemia trials with ERBB2 alterations as inclusion criteria [4].
Malignant Bone Marrow Neoplasm +
ERBB2 is mutated in 0.65% of malignant bone marrow neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant bone marrow neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant bone marrow neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Anti-pd-1/anti-lag-3 dart protein mgd013 and margetuximab are the most frequent therapies in malignant bone marrow neoplasm trials with ERBB2 alterations as inclusion criteria [4].
Adenoid Cystic Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for adenoid cystic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and adenoid cystic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in adenoid cystic carcinoma trials with ERBB2 alterations as inclusion criteria [4].
B-Cell Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and B-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in B-cell neoplasm trials with ERBB2 alterations as inclusion criteria [4].
B-Cell Non-Hodgkin Lymphoma +
ERBB2 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ERBB2 alterations as inclusion criteria [4].
Biliary Tract Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Her2 inhibitor tas0728 is the most frequent therapy in biliary tract neoplasm trials with ERBB2 alterations as inclusion criteria [4].
Brain Metastasis +
ERBB2 is an inclusion criterion in 1 clinical trial for brain metastasis, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and brain metastasis as inclusion criteria, 1 is phase 2 (0 open) [4].
Cabazitaxel and lapatinib are the most frequent therapies in brain metastasis trials with ERBB2 alterations as inclusion criteria [4].
Breast Lobular Carcinoma In Situ +
ERBB2 is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and breast lobular carcinoma in situ as inclusion criteria, 1 is no phase specified (1 open) [4].
Observation and radiation therapy are the most frequent therapies in breast lobular carcinoma in situ trials with ERBB2 alterations as inclusion criteria [4].
Central Nervous System Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Classical Hodgkin Lymphoma +
ERBB2 is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Flx475 and pembrolizumab are the most frequent therapies in classical hodgkin lymphoma trials with ERBB2 alterations as inclusion criteria [4].
Diffuse Gastric Adenocarcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for diffuse gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and diffuse gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Crizotinib and fulvestrant are the most frequent therapies in diffuse gastric adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Ependymoma +
ERBB2 is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Trastuzumab is the most frequent therapy in ependymoma trials with ERBB2 alterations as inclusion criteria [4].
Ewing Sarcoma +
ERBB2 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Pen-866 is the most frequent therapy in Ewing sarcoma trials with ERBB2 alterations as inclusion criteria [4].
Fallopian Tube Clear Cell Adenocarcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ipatasertib and rucaparib are the most frequent therapies in fallopian tube clear cell adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Fallopian Tube Endometrioid Adenocarcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ipatasertib and rucaparib are the most frequent therapies in fallopian tube endometrioid adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Gastric Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Germ Cell Tumor +
ERBB2 is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Palbociclib is the most frequent therapy in germ cell tumor trials with ERBB2 alterations as inclusion criteria [4].
Hepatobiliary Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
High Grade Fallopian Tube Serous Adenocarcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ipatasertib and rucaparib are the most frequent therapies in high grade fallopian tube serous adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Histiocytic And Dendritic Cell Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Pi3k/mtor inhibitor ly3023414 is the most frequent therapy in histiocytic and dendritic cell neoplasm trials with ERBB2 alterations as inclusion criteria [4].
Hypopharyngeal Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cxc chemokine receptor 2 antagonist azd5069, medi-4736, and stat3 antisense oligonucleotide isis 481464 are the most frequent therapies in hypopharyngeal squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Lip And Oral Cavity Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Laryngeal Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Pleural Mesothelioma +
ERBB2 is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Carboplatin and rebastinib tosylate are the most frequent therapies in malignant pleural mesothelioma trials with ERBB2 alterations as inclusion criteria [4].
Malignant Thyroid Gland Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Mga271 and ipilimumab are the most frequent therapies in malignant thyroid gland neoplasm trials with ERBB2 alterations as inclusion criteria [4].
Mantle Cell Lymphoma +
ERBB2 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Ror1 car-specific autologous t-lymphocytes is the most frequent therapy in mantle cell lymphoma trials with ERBB2 alterations as inclusion criteria [4].
NUT Midline Carcinoma Of The Head And Neck +
ERBB2 is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [4].
Mk-8628 is the most frequent therapy in NUT midline carcinoma of the head and neck trials with ERBB2 alterations as inclusion criteria [4].
Oropharyngeal Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Peritoneal Serous Adenocarcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ipatasertib and rucaparib are the most frequent therapies in primary peritoneal serous adenocarcinoma trials with ERBB2 alterations as inclusion criteria [4].
Renal Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for renal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and renal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Ky1044 and atezolizumab are the most frequent therapies in renal carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Renal Pelvis Urothelial Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for renal pelvis urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Gsk3326595 is the most frequent therapy in renal pelvis urothelial carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Renal Pelvis And Ureter Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Atezolizumab is the most frequent therapy in renal pelvis and ureter carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Gland Carcinoma Ex Pleomorphic Adenoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland carcinoma ex pleomorphic adenoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland carcinoma ex pleomorphic adenoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary gland carcinoma ex pleomorphic adenoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Gland Mucoepidermoid Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland mucoepidermoid carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland mucoepidermoid carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary gland mucoepidermoid carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Gland Small Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland small cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary gland small cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
Salivary Gland Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nanoparticle-based paclitaxel suspension and trastuzumab are the most frequent therapies in salivary gland squamous cell carcinoma trials with ERBB2 alterations as inclusion criteria [4].
T-Cell And NK-Cell Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in T-cell and NK-cell neoplasm trials with ERBB2 alterations as inclusion criteria [4].
Thymoma +
ERBB2 is an inclusion criterion in 1 clinical trial for thymoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and thymoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Thyroid Gland Follicular Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Sacituzumab govitecan is the most frequent therapy in thyroid gland follicular carcinoma trials with ERBB2 alterations as inclusion criteria [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
